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When the FLT3 gene is mutated, it originates a modified receptor with structural changes, which give 
survival advantage and malignant hematopoietic cell proliferation. Thus, the presence of mutations in 
this gene is considered an unfavorable prognostic factor. A total of 85 consecutive samples of newly 
diagnosed untreated patients with AL were included in the study after they provided their informed 
consent. FLT3 gene mutations were detected by PCR. For the pediatric group, a positive correlation 
was observed between WBC count and the presence of FLT3-ITD in patients with AML and ALL. 
Furthermore, children with AML who had the FLT3-ITD mutation showed a tendency to express CD34 
in blast cells. In the adult group, the AML patients with FLT3-ITD who expressed CD34 in blast cells 
had a tendency to worse progression. The present data indicate no association between the prognostic 
factors evaluated and FLT3 gene mutations in adult with AL. Yet, the presence of FLT3-ITD mutation 
was significantly related with WBC count in the pediatric group. These findings demonstrate that FLT3 
gene mutations can be considered as independent poor prognostic factors.
Uniterms: FLT3-ITD/mutation. Acute leucemia/prognostic factors. Acute leucemia/adults patients. 
Acute leucemia/pediatric patients. AML. ALL. FLT3-D835.
INTRODUCTION
Acute leukemia (AL) is a group of heterogeneous 
diseases characterized by fast and uncontrolled proliferation 
of hematopoietic progenitor cells in bone marrow, which 
eventually reach the peripheral circulation and can infiltrate 
other organic systems (McCulloch, 1982). In recent 
years, progress in the understanding of genetics and cell-
signaling pathways has provided useful tools to stratify 
acute leukemia patients into different prognostic subgroups 
based on cytogenetic and molecular characteristics (Liersch 
et al., 2014). Prognostic factors in malignant diseases 
are positively or negatively associated with one or more 
outcome parameters. Thus, they prove to be useful in 
deciding upon appropriate therapy (Liersch et al., 2014). 
According to current diagnostic criteria of the World 
Health Organization (WHO) (Swerdlow et al., 2008), 
immunophenotyping, cytogenetics, and molecular genetic 
characteristics, among other prognostic correlations 
such as white-blood-cell (WBC) count, patient age, and 
percentage of blasts are related to prognosis and contribute 
to the stratification of AL (Swerdlow et al., 2008). The 
risk stratification into favorable, intermediate, and adverse 
is based upon cytogenetic risks and molecular genetic 
alterations such as FLT3, KIT, NPM1, and CEPBPA. Among 
these, mutations on the gene that transcribes the FMS-
like tyrosine kinase 3 (FLT3) receptor are very important 
because they are found in approximately 30% of patients 
with acute myeloblastic leukemia (AML) and correlated 
with a poor prognosis (Koh et al., 2009). 
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The FLT3 gene is located in chromosome 13q12 
and encodes a transmembrane protein that plays a crucial 
role in normal hematopoiesis (Baldus et al., 2007). The 
two main types of mutation in this gene are an internal 
tandem duplication (FLT3-ITD) in exons 14 and 15, 
and a missense point mutation in codon 835 in exon 20 
(FLT3-D835). Both mutations produce a constitutively 
active tyrosine-kinase receptor, despite the absence of its 
ligant, leading to disturbance in the normal hematopoiesis 
(Baldus et al., 2007; Small, 2006; Gale, Green, Allen, 
2008). 
In this context, the objective of the present study is 
to evaluate the association between the presence of FLT3 
gene mutations in adults and children with AL and other 
prognostic factors or clinical progression.
PATIENTS AND METHODS
A total of 85 consecutive samples of bone marrow 
and/or peripheral blood were collected from patients 
with AL. The subjects comprised adult patients from 
University Hospital of Federal University of Santa 
Catarina, Florianopolis, Brazil, and pediatric patients from 
Children Hospital Joana de Gusmão of Santa Catarina, 
Florianopolis, Brazil. The samples were collected and 
evaluated for the presence of FLT3 mutations in the period 
of January 2012 to September 2014. All the patients were 
included in the study after they provided their informed 
consent. 
Due to differences in outcome between children and 
adults with AL, patients were divided into pediatric and 
adult groups according to age. Patients below 16 years old 
were considered as belonging to the pediatric group, while 
patients 16 years old or more were included in the adult 
group. A total of 45 patients (22 females and 23 males; 
median age of 41 years, ranging from 16 to 87 years old) 
were included in the adult group, while 40 children (17 
female and 22 male, median age of 4.5 years, ranging from 
one month to 15 years old) were included in the pediatric 
group (Table I).
TABLE I - Clinical and laboratory characteristics of patients diagnosed with LA at the time of diagnosis
ADULT GROUP PEDIATRIC GROUP
Parameters N (45) % N (40) %
Gender 
      Female 
      Male
 
22 
23
 
35.7 
64.3
17 
23
 
42.5 
57.5
Subtipo de leucemia 
      AML 
      LLA
 
27 
18
 
60.0 
30.0
 
12 
28
 
30.0 
70.0
Age (years) 
      Mediana 
      Interval
 
41.0 
16 – 87
 
 
 
4.5 
0.1 - 15
 
CD34 
      Positive 
      Negative
 
28 
17
 
62.2 
37.8
 
35 
05
 
87.5 
12.5
WBC (x103/mm3) 
      Median 
      Interval
 
6.7 
0.4 – 288.7
 
24.5 
2.0 - 450.0
LDH (U/L) 
      Median 
      Interval
 
327.5 
61 - 6.500
 
967.0 
322 - 14.559
Blasts (%) 
      Median 
      Interval
 
38,0 
0,0 - 97,0
 
84,5 
21.0 – 98.0
FLT3 Mutation 
      Positive 
      Negative
 
07 
38
 
08 
32
 
20.0 
80.0
WBC - White-blood-cell; LDH – Lactate dehydrogenase; AL - Acute leukemia.
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Diagnosis and subclassification of AL were based 
on morphological evaluation, immunophenotyping and 
molecular genetic studies [t(15;17), t(8;21), t(16;16) 
and t(9;22)] according to the criteria of the World Health 
Organization Classification of Tumors of Hematopoietic 
and Lymphoid Tissue (Swerdlow et al., 2008). Because 
many patients did not have karyotype request or because 
patient’s samples did not have cell growth, it was not 
possible to access all karyotypes results from all patients 
included in this study. Thus, only the results of genetic 
alterations investigated by molecular biology were 
considered for AL classification. A total of 39 patients 
were diagnosed with AML (27 adults and 12 children) and 
46 patients with acute lymphoblastic leukemia (ALL - 18 
adults and 28 children). The distribution was as follows: 
AML (5 cases; 5.9%), AML without maturation (5 cases; 
5.9%), AML with maturation (6 cases; 7.0%), AML with 
t(8;21) (1 case; 1.2%), acute promyelocytic leukemia 
with t(15;17) (14 cases; 16.5%), acute myelomonocytic 
leukemia (1 case; 1.2%), acute monoblastic leukemia 
(5 cases; 5.9%), acute monocytic leukemia (1 case; 
1.2%), acute megakaryoblastic leukemia (1 case; 1.2%), 
B-derived ALL (35 cases; 41.2%), B-derived ALL with 
t(9;22) (2 cases; 2.3%) and T-derived ALL (9 cases; 
10.5%).
For the analysis of correlation between the presence 
of FLT3 mutations (ITD or D835) and age or WBC count, 
the adult and pediatric groups were divided according to 
prognosis. For the adult group, age above 50 years for 
AML and over 60 years for ALL were considered poor 
prognosis. Regarding WBC count, AML and ALL were 
considered of poor prognosis when counts were greater 
than 20.0x103/mm3 and 10.0x103/mm3, respectively. For 
the pediatric group, age above nine years and WBC count 
greater than 50.0x103/mm3 were included in the poor 
prognosis group. Moreover, the association between the 
presence of FLT3 gene mutations and the progression of 
patients after six months of diagnosis was also evaluated; 
the patients were divided into four groups: remission, 
relapse, death in remission, and death without remission.
Genomic DNA extraction
The peripheral blood was use only in the cases 
that WBC was above 20.0x103/mm3 and perceptual of 
blast cells were about 20% at diagnosis. Due the fact 
that the method of detecting the FLT3 mutation with 
polymerase chain reaction (PCR) has a limit of detection of 
approximately 1 in 100 cells (Murphy et al., 2003), when 
the peripheral blood samples did not match this criterion, 
the bone marrow sample was used. DNA from peripheral 
blood or bone marrow was obtained using the commercial 
QIAmp DNA kit (QIAGEN, USA). Briefly, 200 μL of the 
sample was mixed with 20 μL QIAGEN protease in a 1.5 
mL microtube. Cells were lysed using 200 μL of AL buffer 
in the sample, homogenized for 15 seconds and incubated 
at 56 °C for 10 minutes. Absoluted ethanol (96-100%) 
was added and again the samples were homogenized for 
15 seconds. The obtained solution was transferred to the 
QIAamp column and centrifuged at 6,000 x g for 1 minute. 
The filtrate was discarded and 500 μL AW1 wash solution 
was added and the column was centrifuged at 6,000 x g for 
1 minute. The column was washed by adding 500 μL of a 
second wash buffer (AW2) and centrifuged at 20-20,000 
x g for 3 minutes. The purified DNA was eluted from 
the spin columns with 100 µL of buffer AE or 100 μL of 
distilled water. Subsequently, the column was incubated 
for 5 minutes at room temperature and centrifuged at 6,000 
x g for 1 minute. The obtained DNA was stored at -20 °C 
to be used in the next PCR reaction.
Detection of FLT3-ITD mutation
The Polymerase Chain Reaction (PCR) technique 
was employed to detect FLT3-ITD mutation. The 
primers 5’-GCAATTTAGGTATGAAAGCCAGC-3’ 
and 5’-CTTTCAGCATTTTGACGGCAACC-3’ used to 
amplify exons 14 and 15 of the FLT3 gene were previously 
described by Meshinchi et al. (2001) (Meshinchi et 
al., 2006). The PCR products were visualized in 12% 
polyacrylamide denaturing gel with ethidium bromide 
staining under 320 nm UV light transilluminator. The 
presence of ITD mutation in the FLT3 gene was determined 
by visualization of a single band larger than 329 bp, wild-
type gene fragment (homozygous mutation), or by the 
visualization of 329 bp wild-type gene fragment and 
one or more fragments larger than 329 bp (heterozygous 
mutation) as demonstrated in Figure 1. All PCR reagents 
were purchased from Invitrogen (Carlsbad, CA, USA).
Detection of FLT3-D835 mutation
The PCR technique followed by the restriction 
fragment length polymorphism (RFLP) technique 
described by Liang et al. (2003) were used to detect 
the FLT3-D835 mutation (Liang et al., 2003). First, the 
region of exon 20 of the FLT3 gene was amplified using 
specific primers (5’-CCGCCAGGAACGTGCTTG-3’ 
and 5’-GCAGCCTCACATTGCCCC-3’). Next, the PCR 
products underwent enzymatic digestion with the enzyme 
ECO-RV. The digestion products were visualized in a 12% 
polyacrylamide gel with ethidium bromide staining under 
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320 nm UV light transilluminator. The samples without 
mutation underwent complete enzymatic digestion, which 
resulted in the presence of two bands (68 bp/46 bp). 
Heterozygous samples for FLT3-D835 mutation showed 
three bands (114 bp/68 bp/46 bp) after digestion, while 
homozygous samples showed a completely undigested 
band of 114 bp (Figure 2). All PCR reagents were 
purchased from Invitrogen (Carlsbad, CA, USA).
Statistical analysis
The association between the presence of FLT3 
mutations and nominal variables such as gender, CD34 
expression, WBC count at diagnosis, and patient 
outcome after six months of diagnosis were analyzed 
using the Chi-square test. Numeric variables such as 
lactate dehydrogenase activity (LDH) and percentage of 
blasts were associated with the group of interest using 
Mann-Whitney U test. A p-value ≤0.05 was considered 
statistically significant for all analyses. Statistical analyses 
were done with the software SPSS (version 17.0).
RESULTS
During the period of this study, 85 samples of bone 
marrow and/or peripheral blood from patients with AL 
were evaluated for the presence of FLT3 mutations. 
As displayed in Table II, the FLT3-ITD mutation 
was observed in three patients in the adult group (6.7%) 
and FLT3-D835 mutation in five patients (11.1%). In the 
pediatric group, FLT3-IDT mutation was observed in 
seven patients (17.5%) and FLT3-D835 mutation in just 
one patient (2.5%).
According to the subtype in the adult group, it was 
observed that, of all cases of AML, 7.4% (two cases) 
and 14.8% (four cases) had FLT3-ITD and FLT3-D835, 
respectively. In adult patients with ALL, 5.6% (one case) 
had either FLT3-ITD or FLT3-D835. These results show 
that there was no correlation between AL subtype and 
presence of ITD or D835 mutations in adult patients.
The same was observed with the pediatric group, 
where 33.3% (four cases) of the patients with AML had 
the FLT3-ITD mutation, while 10.7% (three cases) of the 
patients with ALL showed the same mutation. Although 
the FLT3-ITD mutation was not associated with the AL 
subtypes (AML or ALL; P=0.168), it was observed that 
this mutation was more prevalent in children with AML. 
Mutation FLT3-D835 was detected only in one child 
(8.3%) with AML.
Regarding gender, FLT3 mutations were present in 
20.8% (five cases) of males and 13.6% (three cases) of 
females in the adult group. In the pediatric group, 17.4% 
(four cases) and 23.5% (four cases) of males and females, 
respectively, showed FLT3 mutations. No correlation was 
found between gender and the presence of FLT3 mutations 
in either group.
As presented in the Table II, there was no correlation 
between the presence of FLT3-ITD or FLT3-D835 and 
prognostic factors such as age, WBC count, percentage 
of blasts, CD34 expression, and LDH activity in the adult 
group. However, it is important to note that the patients 
who had FLT3-ITD mutation showed WBC count (median 
29.4 x103/mm3) and LDH activity (median 875.0 U/L) 
above the upper reference values (11.0x103/mm3 and 190.0 
U/L, respectively). 
As demonstrated in Table III, for the pediatric group, a 
FIGURE 1 - PCR products of FLT3-ITD, analyzed by gel 
electrophoresis. Reverse view of ethidium-bromide-stained 12% 
polyacrylamide gel FLT3-ITD was detected as extra-bands in 
addition to normal band of 329 bp. Line 1- Molecular weight 
marker (50 bp); Line 2-Water control; Line 3-Patient sample 
wild type; Line 4- Patient sample with FLT3-ITD mutation; 
Line 5-wild type control; Line 6-) FLT3-ITD mutation control.
FIGURE 2 - PCR products of FLT3-D835, analyzed by gel 
electrophoresis. Reverse view of ethidium-bromide-stained 
12% polyacrylamide gel FLT3-D835 was detected as extra-
band after enzymatic digestion in addition to normal bands of 
68 bp and 46 bp. Line 1- Molecular weight marker (50 bp); Line 
2-PCR product of a patient sample with FLT3-D835 mutation 
before enzymatic digestion; Line 3-PCR product of a patient 
sample with FLT3-D835 mutation after enzymatic digestion ; 
Line 4-PCR product of a patient sample with wild type before 
enzymatic digestion; Line 5-PCR product of a patient sample 
with wild type after enzymatic digestion; Line 6-Water control.
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positive correlation was observed between WBC count and 
the presence of FLT3-ITD in patients with AML (p=0.007) 
and ALL (p=0.005). Furthermore, children with AML who 
had the FLT3-ITD mutation showed a tendency to express 
CD34 (p=0.078). Similar to the adult group, children who 
had FLT3-ITD mutation showed LDH activity (median 
1,292.0 U/L) above the maximum reference value. There 
was no correlation between FLT3-D835 mutation and the 
prognostic factors for the pediatric group. The association 
between the presence of FLT3 gene mutations and the 
patient progression after six months of diagnosis was also 
evaluated. In the adult group, the AML patients with FLT3-
ITD who expressed CD34 tended to worse progression 
(p=0.067). Regarding the pediatric group, there were no 
significant correlations between patient progression and 
presence of FLT3 gene mutations.
DISCUSSION
Treatment of patients with FLT3 mutation represents 
a great clinical challenge. Patients with these mutations 
carry a particularly poor prognosis, with greater relapse 
rate, and inferior overall survival when compared to 
patients with AL without this mutation (Taketani et al., 
2004; Fedders et al., 2015; Wellmann et al., 2015). Given 
the poor prognosis of patients with AL and FLT3 mutation, 
mainly FLT3-ITD, it has become a common practice to 
do allogeneic bone marrow transplantation during first 
remission in patients with these mutations. However, there 
remains a significant relapse rate following transplant for 
FLT3-ITD, and it is possible that maintenance therapy with 
FLT-3 inhibitors will reduce the recurrence rates (Taketani 
et al., 2004; Bornhauser et al., 2007; Schlenk et al., 2008; 
Dezern et al., 2011; Hassanein et al., 2016). Recently, 
FLT3 inhibitors have emerged as a new option of treatment 
for these patients. Several FLT3 inhibitors have been tried 
as monotherapy or combined with other chemotherapeutic 
agents (Hassanein et al., 2016). 
Nevertheless, it is still unclear how and when 
these agents should be use during AML treatment 
(Hassanein et al., 2016). Because of the impact of FLT3 
mutation on prognosis and treatment protocols, the 
guidelines from various major organizations, such as 
National Comprehensive Cancer Network and European 
LeukemiaNet, recommend FLT3 mutation analysis on 
diagnosis.
TABLE II - Values of age, percentage of blasts, WBC count, LDH activity, CD34 expression, and progression of patients with AL 
according to the absence or presence of FLT3 mutation and group
ADULT GROUP
Presence of FLT3 mutation (n=7) Absence of FLT3 mutation (n=38)
Median Limits Median Limits
Age (years) 41.0 25.0 - 73.0 41.0 15.0 - 87.0
Blasts (%) 50.0 27.0 - 96.0 46.0 0.0 - 98.0
WBC (x103/mm3) 12.9 1.6 - 288.7 5.9 0.4 - 177.2
LDH (U/L) 875.0 259.0 - 5,189.0 300.0 61.0 - 6,500.0
N % N %
CD34 Expression 4 57.2 24 63.1
Death 3 42.8 18 47.4
Remission 4 57.2 20 52.6
PEDIATRIC GROUP
Presence of FLT3 mutation (n=8) Absence of FLT3 mutation (n=32)
Median Limits Median Limits
Age (years) 6.5 0.10 - 14.0 4.0 0.3 - 14.0
Blasts (%) 83.0 80.0 - 96.0 83.0 21.0 - 98.0
WBC (x103/mm3) 51.3 27.5 - 220.0 14.8 2.0 - 450.0
LDH (U/L) 1,227.0 786.0 - 13,087.0 955.0 322.0 - 14,559.0
N % N %
CD34 Expression 7 87.5 28 87.5
Death 5 62.5 8 25.0
Remission 3 37.5 24 75.0
WBC - White-blood-cell; LDH – Lactate dehydrogenase; AL - Acute leukemia.
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Worldwide, the reported incidence of FLT3-ITD 
in adults with AML is 15-35% (Nakao et al., 1996; Abu-
Duhier et al., 2000; Kottaridis et al., 2001; Xu et al., 
2005; Amir, Yi-Bin, 2011). Additionally, the FLT3-D835 
mutation incidence is 8-12% in AML cases (Small, 2006). 
Lucena-Araujo et al. demonstrated that the incidence 
of FLT3-ITD in Brazilian patients with AML is similar 
to the other countries, but the FLT3-TKD is lower. This 
reinforces the idea that there are geographic differences 
in FLT3 mutation frequency. Considering that Brazil 
has continental proportions and multiethnic population, 
it is expected that the incidence of these mutations are 
different among Brazilian regions. The incidence and 
clinical relevance of FLT3 mutations in AL patients 
from Santa Catarina are unknown, and it is important to 
create regional data to establish public health policies that 
improve AL with FLT3 mutation treatments in this region 
(Lucena-Araujo et al., 2010). 
The results of this study showed a lower frequency 
of FLT3-ITD mutation (7.4%). This discrepancy can be 
explained by one of the two facts: i) the small number 
of patients included in the study, or ii) the intrinsic 
characteristics of the population studied. Furthermore, 
it should be noted that, as mentioned by Bao et al. 
(2006), the incidences reported in other studies might be 
overestimated because the mutation analysis was usually 
performed on archived samples from patients who usually 
have leukocytosis, which is generally present in AML 
carrying FLT3 mutations (Bao et al., 2006). On the other 
hand, the incidence of the FLT3-ITD mutation in adults 
with ALL described in other studies (5 - 10%) is similar 
to that found in the present study (5.6%) (Kottaridis et 
TABLE III - Association between prognostic factors and presence of FLT3-IDT and FLT3-D835 mutations in adults with acute 
leukemia
LMA (n=27) LLA (n=18)
FLT3-ITD 
(P values)
FLT3-D835 
(P values)
FLT3-ITD 
(P values)
FLT3-D835 
(P values)
Agea 0.430 0.608 0.167 0.500
WBC count at diagnosisa 0.156 1.000 0.444 0.444
% Blasts 1.000 0.612 0.111 0.667
CD34 expression 0.091 0.609 0.111 1.000
LDH 0.271 0.157 0.556 0.222
WBC - White-blood-cell; LDH – Lactate dehydrogenase; a For this analysis the variables age and WBC count at diagnosis were 
divided into two groups according to prognosis, as follows: Age - poor prognosis is ≥50 years old for AML and ≥60 years old 
for ALL, good prognosis is <50 years old for AML and <60 years old for ALL; WBC - poor prognosis is ≥20,000/mm3 for AML 
and ≥10,000/mm3 for ALL, good prognosis is <20,000/mm3 for AML and <10,000/mm3 for ALL. * P≤0.05 is considered to be 
statistically significant.
TABLE IV - Association between prognostic factors and presence of FLT3-ITD and FLT3-D835 mutations in children with acute 
leukemia
LMA (n=12) LLA (n=28)
FLT3-ITD 
(P values)
FLT3-D835 
(P values)
FLT3-ITD 
(P values)
FLT3-D835 
(P values)
Agea 0.295 0.417 0.904 -
WBC count at diagnosisa 0.007* 1.000 0.005* -
% Blasts 0.093 0.167 0.856 -
CD34 expression 0.078 1.000 0.124 -
LDH 0.111 0.667 0.514 -
WBC - White-blood-cell; LDH – Lactate dehydrogenase. a For this analysis, the variables age and WBC count at diagnosis were 
divided into two groups according to prognosis, as follows: Age - poor prognosis is ≥9 years old, good prognosis is <9 years old; 
WBC: poor prognosis is >50,000/mm3 for AML and ALL; LDH – lactate dehydrogenase. * P≤0.05 is considered to be statistically 
significant. 
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al., 2001; Amir, Yi-Bin, 2011). However, because only 
one case was identified in this study, it was difficult to 
assess properly the relation between this mutation and the 
prognostic factors.
The incidence of FTL3-ITD in children with AML 
is lower than in adults (5-16%) (Gale, Green, Allen, 
2008). Regarding this aspect, the results obtained in this 
study showed higher percentages (33.3%). To the best 
of our knowledge, Al-Tonbary et al. (2009) conducted 
the only available study on the presence of FLT3-ITD in 
children with ALL. Unlike the present study, which found 
an incidence of 10.7%, Al-Tonbary et al. reported that 
children with ALL did not show the FLT3-ITD mutation. 
As in the case of the adult group, this difference can be 
explained by the small number of patients included in this 
study and by the intrinsic characteristics of the population 
studied.
In this study, FLT3-D835 incidence rate was 14.8% 
in AML cases, which is higher than the rates reported in 
other works (Small, 2006; Lucena-Araujo et al., 2010). 
In ALL cases, our results showed FLT3-D835 frequency 
of 5.6%, with contrast with the literature results, that 
demonstrated a frequency of 1-3% (Abu-Duhier et al., 
2001; Yamamoto et al., 2001; Thiede et al., 2002). 
Concerning the FLT3-D835 mutations in the 
pediatric group, there was only one case of AML (8.3%) 
and no ALL case positive for the mutation. The frequency 
of this mutation in AML children is in agreement with that 
mentioned in other pieces of research, which report it as 
rare (7 - 10%) (Meshinchi et al., 2006; Markova et al., 
2009). However, the reported incidence of FLT3-D835 
in ALL children is 7.5% (Wang et al., 2010), which is 
higher than that found in the present study. Based on 
the incidences described for FLT3-ITD and FLT3-D835 
mutations, a variation was observed among studies, which 
indicates that there are differences in the frequency of these 
mutations according to geographical areas.
In relation to the distribution of FLT3 mutations 
according to gender, the present study is consistent with 
other findings where there is no significant correlation 
between these two variables (Al-Tonbary et al., 2009; 
Karabacak et al., 2010).
The prevalence of FLT3 mutations increases with 
age, but the presence of this mutation seems to have less 
impact as a prognostic factor in patients above 60 years 
old than other adverse prognostic factors (Foran, 2010). In 
this study, no relation was observed between patient age 
and the presence of FLT3 mutations in either group, which 
is in agreement with other studies, which also found no 
association between these variables (Parcell et al., 2006; 
Wang et al., 2010). 
WBC count, LDH activity, and cytogenetic 
abnormalities at diagnosis are important prognostic 
factors (Stone, 2009), as are the mutations in the FLT3 
gene (Betz, Hess, 2010). The findings related to whether 
there is a correlation between the mutations in FLT3 gene 
and WBC count are controversial. While some groups 
reported an association between these two variables 
in AML patients (Kottaridis et al., 2001; Thiede et al., 
2002; Emerenciano et al., 2008; Peng et al., 2008; Wang 
et al., 2010), others found no such relationship (Schlenk 
et al., 2008; Karabacak et al., 2010). According to the 
classification of genetic abnormalities, mutations in the 
FLT3 gene are considered class I mutations, which confer 
a survival advantage and increase cell proliferation (Betz, 
Hess, 2010). This may explain why so many studies found 
an association between mutations in the FLT3 gene and 
WBC count. In the present study, this relationship was 
not statistically significant in the adult group, but it was 
observed that the total WBC count was higher for patients 
who had the FLT3-ITD mutation. In the pediatric group, a 
significant association was observed between high WBC 
and presence of FLT3-ITD mutation. 
In patients with AL, an increase in LDH activity is 
considered a poor prognostic factor (Varma, Varma, 2008). 
A study with adult AL patients showed an association 
between the presence of FLT3 gene mutations and increase 
in LDH activity (Peng et al., 2008). However, this same 
observation was not found in another study (Karabacak et 
al., 2010), as well as in the present one. Nevertheless, in 
both the adult and the pediatric groups, patients with FLT3 
gene mutations showed higher LDH activity (875.0 U/L 
and 1,227.0 U/L, respectively) than the highest reference 
limit (190.0 U/L).
Although the patients with FLT3 gene mutations 
included in this study had high percentages of blast cells in 
both groups, as reported by Liu et al. (2007), the presence 
of FLT3 gene mutations and percentage of blasts were not 
statistically related.
Another relevant prognostic factor is the CD34 
expression in blast cells. A study by Zhu et al. (2013) 
showed that CD34 expression is an FLT3-ITD-independent 
predictor of poor prognosis. In contrast, other studies 
reported an association between FLT3-ITD mutation 
and the presence of the CD34 marker in AML patients 
(Barragán et al., 2011; Zhu et al., 2013). In the present 
study, no correlation between FLT3 gene mutations and 
CD34 expression were found. However, four of the five 
positive patients for FLT3-D835 expressed CD34.
Several studies demonstrated that the presence of 
FLT3-ITD in AML patients might indicate unfavorable 
disease course including higher death rate and shorter 
G. Burnatt, M. A. Licínio, P. C. Gaspar, A. S. Ferreira, M. L. Reis, A. C. R. Moraes, T. C. M. Sincero, M. C. Santos-Silva
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disease-free survival clearly associated with leukocytosis. 
These findings classify FLT3-ITD as a poor-prognostic 
mutation (Zhu et al., 2013). Mathews et al. (1991) suggest 
that there is an inverse relationship between the rate of 
molecular remission and patients with the presence of 
FLT3-ITD mutation. In the present study, no association 
was found between the presence of FLT3-ITD mutation 
and a poor outcome (death or relapse) in adult patients. 
Nevertheless, the AML pediatric group showed a tendency 
of association between FLT3-ITD and death, which 
characterizes it as an indicator of poor prognosis. Studies 
have not shown a significant relation between FLT3-D835 
mutation and complete remission, disease-free survival, or 
overall survival (Matthews et al., 1991; Wang et al., 2010). 
These findings are consistent with the results presented in 
this study. 
CONCLUSIONS
In conclusion, the present analysis showed that there 
is no association between the evaluated prognostic factors 
such as age, LDH activity, and CD34 expression and FLT3 
gene mutations in adult and pediatric patients with AL. 
Nevertheless, the presence of FLT3-ITD mutation was 
significantly related to WBC count in the pediatric group. 
These results suggest that the FLT3 gene mutations are 
independent poor prognostic factors.
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